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BACKGROUND: This multicentre, international phase II trial evaluated the efficacy and safety profile of a first-line combination of oral
vinorelbine plus capecitabine for women with metastatic breast cancer (MBC).
METHODS: Patients with measurable, HER2-negative disease received, as a first line in metastatic setting, 3-weekly cycles of oral
vinorelbine 80mgm
 2 (after a first cycle at 60) on day 1 and day 8, plus capecitabine 1000mgm
 2 (750 if X65 years of age) twice
daily, on days 1–14. Treatment was continued until progression or unacceptable toxicity.
RESULTS: A total of 55 patients were enrolled and 54 were treated (median age: 58.5 years). Most (78%) had visceral involvement and
63% had received earlier (neo)adjuvant chemotherapy. The objective response rate (RECIST) in 49 evaluable patients was 51% (95%
confidence interval (CI), 36–66), including complete response in 4%. The clinical benefit rate (response or stable disease for X6
months) was 63% (95% CI, 48–77). The median duration of response was 7.2 months (95% CI, 6.4–10.2). After a median follow-up
of 41 months, median progression-free survival was 8.4 months (95% CI, 5.8–9.7) and median overall survival was 29.2 months (95%
CI, 18.2–40.1). Treatment-related adverse events were manageable, the main grade 3–4 toxicity was neutropaenia (49%); two
patients experienced febrile neutropaenia and three patients had a neutropaenic infection (including one septic death). A particularly
low rate of alopaecia was observed.
CONCLUSION: These results show that the all-oral combination of oral vinorelbine and capecitabine is an effective and well-tolerated
first-line regimen for MBC.
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Breast cancer is among the most common cancers in Western
countries. Advanced breast cancer is the leading cause of death in
women aged from 40 to 54 years. About one in eight Western
women will develop breast cancer if they live up to an age of 85
years. Despite improving locoregional and adjuvant treatment,
many patients still develop recurrent and/or metastatic breast
cancer (MBC) within 10 years and will subsequently die of the
disease (Harris et al, 2000).
There is no single standard of care for patients with MBC, as
treatment plans require an individualised approach based on
multiple factors, including tumour biology, growth rate of disease,
presence of visceral metastases, history of earlier therapy and
response, risk for toxicity and patient preference (O’Shaughnessy,
2005). Preferred first-line single agents in advanced breast
cancer are anthracyclines, taxanes, capecitabine, gemcitabine and
vinorelbine (NCCN Guidelines, 2009). More recently, bevacizumab
has been evaluated in combination with taxanes with interesting
clinical results. With anthracyclines and taxanes being used
increasingly in early-stage setting, there is an even greater need
for other active options in advanced setting to improve outcomes
and/or quality of life. The development of oral chemotherapy
formulations should allow a higher efficiency, by providing
consistent efficacy and reduced patient constraints.
A phase II trial has evaluated oral vinorelbine (Navelbine Oral)
single agent as first-line chemotherapy for locally advanced
or metastatic breast cancer, showing an overall response rate
of 31% and a median progression-free survival (PFS) of 17.4 weeks
(Freyer et al, 2003). Capecitabine (Xeloda) as a single agent
has been largely studied in pre-treated metastatic patients,
with a median response rate of 28% and a median time to
progression of 4.7 months (Ershler, 2006). Both agents have been
included among commonly used compounds for the treatment
of MBC in ESMO Clinical Recommendations (Kataja and
Castiglione, 2008).
After establishing both oral vinorelbine and capecitabine as
a standard of care in MBC, the development of the combination
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sof both agents has a very strong rationale. Moreover, the two
agents have different mechanisms of action, different and
acceptable safety profiles and synergistic antitumour activity in
preclinical models (Sawada et al, 2002). The combination
of intravenous vinorelbine (Navelbine) and capecitabine has
shown promising efficacy in MBC (Hess et al, 2004; Ghosn
et al, 2006; Iodice et al, 2006; Welt et al, 2006; Palumbo et al,
2008). By combining oral vinorelbine and capecitabine, similar
outcomes might be achieved without the burden of intravenous
infusion.
Three phase I trials have evaluated the combination of oral
vinorelbine and capecitabine in MBC (Kellokumpu-Lehtinen et al,
2006; Nole et al, 2006; Anton et al, 2008). In all these studies, the
recommended dose of capecitabine for phase II trials was
1000mgm
 2 twice daily, on days 1–14. As special caution is
needed with capecitabine in combination for elderly patients, the
doses administered in this trial were reduced to 750mgm
 2 twice
daily, on days 1–14 if age was X65 years. Regarding
oral vinorelbine, different schedules have been evaluated and,
among these options, we evaluated in our trial the schedule of
60mgm
 2 on days 1 and 8 for cycle 1, with a dose escalation to
80mgm
 2 for subsequent cycles in the absence of grade 3 or 4
haematological toxicity.
This international, open-label, phase II trial was designed to
evaluate the activity and safety of an all-oral combination of oral
vinorelbine and capecitabine as first-line therapy for patients with
HER2-negative MBC.
MATERIALS AND METHODS
Eligibility criteria
Eligible patients were female, X18 years, with documented
metastatic breast adenocarcinoma untreated by chemotherapy.
Other inclusion criteria included HER2-negative disease (IHC 0–1
or IHC 2þ confirmed as FISH negative), Karnofsky performance
status X70%, at least one measurable lesion according to
RECIST criteria (Therasse et al, 2000) and a life expectancy X16
weeks. Adjuvant or neoadjuvant chemotherapy containing
an anthracycline and/or a taxane was allowed if X6 months had
elapsed between the last dose of chemotherapy and documentation
of relapse. Earlier hormone therapy for advanced disease was
allowed. Patients were required to have adequate bone marrow and
hepatic and renal functions, indicated by haemoglobin X10g per
100ml, absolute neutrophil count X2 10
9 per l, platelet count
X100 10
9 per l, total serum bilirubin p1.5 upper normal limit
(UNL), AST/ALT p2.5 UNL, (p3.5 UNL in case of liver
metastases), alkaline phosphatase p2.5 UNL (or p5 UNL for bone
metastases) and creatinine clearance 450mlmin
 1 (calculated
using the Cockroft and Gault formula). Patients were required to
give written informed consent before study-specific procedures
were performed and to comply with protocol for the duration of
the study.
Patients were ineligible if they had only local relapse, earlier
chemotherapy in a metastatic setting, previous exposure to a
vinca-alkaloid or capecitabine, serious illness or medical condi-
tions such as cardiac disease, unstable diabetes, uncontrolled
hypercalcaemia, severe peripheral neuropathy, active infection
or previous organ allograft. Patients were also excluded if they
were pregnant or lactating, required a concurrent use of the
antiviral sorivudine or a chemically related analogue such as
brivudine, had clinical central nervous system (CNS) or leptome-
ningeal metastases, had a malabsorption disease that may
affect absorption or oral chemotherapy, had possible hypersensi-
tivity to fluoropyrimidine therapy, had participated in another
clinical trial with any investigational drug within 30 days before
study inclusion or had a history of another malignancy except
cured basal-cell carcinoma of the skin or excised carcinoma in situ
of the cervix.
Primary and secondary end points
The primary end point of the study was overall response. Overall
response was defined as the best confirmed response recorded
from the date of registration until the end of study period.
Secondary objectives included the evaluation of safety, duration of
response, PFS and overall survival.
Treatment plan
Treatment was provided in 3-weekly cycles. Oral vinorelbine was
administered at 60mgm
 2 on days 1 and 8 of the first cycle and
escalated to 80mgm
 2 at cycle 2 and subsequent cycles in the
absence of grade 3 or 4 haematological toxicity.
Capecitabine was administered at a dose of 1000mgm
 2
twice daily, on days 1–14 (750mgm
 2 twice daily for patients
X65 years).
Prophylactic oral antiemetic medication with a 5-HT3 antagonist
was recommended before each oral vinorelbine administration.
Treatment was continued until disease progression, unaccep-
table toxicity or patient’s refusal.
Dose modifications
Dose adjustments and/or treatment delays could be made in the
event of dose-limiting haematological or non-haematological
toxicities. If study treatment could not be administered after two
delays (meaning 2 weeks) of the theoretical day 1 because of any
toxicity, it had to be permanently discontinued. Thus, the
maximum interval between the start of one cycle and the next
was 5 weeks. If one of the agents had to be permanently
discontinued, the patient was withdrawn from the study.
Oral vinorelbine was not administered if patients had grade X2
neutropaenia, and capecitabine was interrupted in case of grade
X3 neutropaenia. After one episode of grade 3 or 4 neutropaenia,
the dose of oral vinorelbine was permanently decreased to
60mgm
 2 for subsequent cycles. Patients experiencing grade 3
or 4 neutropaenia, with or without fever, were allowed to receive
a granulocyte colony-stimulating factor (G-CSF) in subsequent
cycles at the investigator’s discretion. If AST/ALT/alkaline
phosphatase increased to 45.0 UNL, or if bilirubin increased to
41.5 UNL, both agents were not administered and a reassessment
was carried out a week later. If grade X2 diarrhoea or hand–foot
syndrome occurred, administration of capecitabine was inter-
rupted until it resolved to grade 0 or 1 and doses were decreased by
25% (if grade 3) or 50% (if grade 4) for subsequent cycles.
Study assessments
Every patient who entered the study underwent baseline assess-
ments, including medical history, physical examination, perfor-
mance status, HER2 testing (either on the primary tumour or on a
metastatic site), electrocardiogram and chest X-ray. Tumour
measurements by imaging were determined as clinically indicated
by computed tomography (CT), abdominal ultrasound, bone scan
and/or brain CT scan (if suspicion of CNS involvement). Complete
blood cell counts were carried out within 2 days before each oral
vinorelbine administration.
Responses were assessed every two cycles until disease
progression, or more frequently if early progression was suspected.
The best overall response achieved, according to RECIST criteria,
was reported for each patient. A complete response (CR) required
a complete disappearance of all lesions, and a partial response
(PR) required at least a 30% decrease of the sum of the longest
diameters of target lesions. Both CR and PR had to be confirmed at
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sleast 4 weeks later. Stable disease (SD) was defined as neither
sufficient shrinkage to qualify for PR nor sufficient increase to
qualify for progressive disease (PD). Progressive disease was
defined as at least a 20% increase in the sum of longest diameters
of target lesions and/or the appearance of new lesions. Clinical
benefit was defined as patients achieving CR, PR or SD, maintained
for a minimum of 6 months.
Adverse events and medical history were recorded throughout
the study. The severity of adverse events was graded according to
NCI common toxicity criteria version 2.0.
Statistical analysis
The one-sample multiple testing procedure for phase II clinical
trials as described by Fleming (1982) was used. This procedure
uses the standard single-stage test procedure at the last one of two
pre-specified tests, while allowing for early termination (should
extreme results be seen) and essentially preserving the size and
power of the single-stage procedure.
On the basis of a type I error rate of 5% and a 95% power to
reject the null hypothesis of a 25% objective response rate
(complete or partial), a sample size of 55 patients was needed.
All treated patients were included in the intent-to-treat (ITT)
analysis and were analysed for safety. The evaluable population
was defined as all patients eligible for the trial who underwent a
full evaluation of target and non-target lesions and had received at
least two cycles of study treatment (including patients with PD
documented before the second cycle).
Response rate and clinical benefit were tabulated together with
95% confidence interval (CI), following the exact method. The
Kaplan–Meier method was applied to overall survival, PFS and
duration of response. Subset analysis (according to baseline
characteristics) was performed for response rate.
RESULTS
Patient characteristics
Between March 2004 and June 2005, 55 patients with MBC were
enrolled from 13 sites in six countries. One patient who entered
into the study did not receive study treatment because of the
presence of a major exclusion criterion (low creatinine clearance).
Five of the remaining 54 patients were not evaluable for response,
but were included in the ITT analysis: one patient was not eligible
for the study (no measurable disease as defined in the protocol),
two patients were not assessable as a result of premature study
discontinuation (one patient withdrew from the study after the
first therapy administration owing to abdominal pain, the second
patient died during the second cycle from sepsis) and two patients
having received three and six cycles did not undergo a full
evaluation of all target and non-target lesions. Therefore, 49
patients with measurable disease were assessable for disease
response per protocol.
The patients’ characteristics are described in Table 1. Patients
typically had visceral metastases and a good performance status.
All had HER2-negative disease. Sixty-three percent of patients had
received earlier (neo)adjuvant chemotherapy, including an
anthracycline in the majority and a taxane in some cases.
Clinical efficacy
The objective response rate was 51% among the 49 evaluable
patients (95% CI, 36.3–65.6), including CRs in 4.1%. Clinical
benefit (CRþPRþSD X6 months) was 63.3% (95% CI, 48.3–
76.6). In the ITT population, the objective response rate was 46.3%
(95% CI, 32.6–60.4). Median time to response was 3.1 months
(range 1.3–6.7) and median duration of response was 7.2 months
(95% CI, 6.4–10.2) (Table 2).
A subanalysis of responses according to patients’ characteristics
is shown in Table 3. It is noteworthy that the response rate in
patients with liver involvement (52.2%) was similar to the rate in
the overall population.
After a median follow-up of 41 months, 20 of the 54 patients
treated in the study were still alive. Median PFS was 8.4 months
Table 1 Patient characteristics
Characteristics N¼54 (%)
Median age 58.5 years
Range (31.0–84.0)
o65 32 59.3
X65 22 40.7
Karnofsky performance status at baseline
70/80 11 20.4
90/100 43 79.6
Hormonal status
ER+/PR+ 29 53.6
ER+/PR  9 16.7
ER /PR+ 2 3.7
ER /PR  9 16.7
ER and/or PR unknown 5 9.3
Prior chemotherapy (early stage) 34 63.0
Type of Chemotherapy
Anthracycline-based without taxane 23 42.6
Anthracycline+taxane 6 11.1
CMF 5 9.3
Prior hormone therapy 41 75.9
For advanced disease 27 50.0
Number of metastatic sites
1 7 13.0
2 22 40.7
42 25 46.3
Visceral involvement 42 77.8
Metastatic sites
Liver/lung metastases 26/25 48.1/46.3
Bone metastases 33 61.1
Skin/soft tissue 3/5 5.6/9.3
Median delay between diagnosis and first relapse 34.3 months
Table 2 Response to treatment
Objective response rate (RECIST)
Evaluable population n¼49 (%)
CR 2 4.1
PR 23 46.9
Objective response – CR+ PR   (95% CI) 25 51.0 (36.3–65.6)
SD 14 28.6
PD 10 20.4
Clinical benefit (CR+PR+SD X6 months) (95% CI) 31 63.3 (48.3–76.6)
Median time to response (range) 3.1 months (1.3–6.7)
Median duration of response (95% CI) 7.2 months (6.4–10.2)
CI¼confidence interval; CR¼complete response; PR¼partial response;
SD¼stable disease.
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s(95% CI, 5.8–9.7 – Figure 1). Median PFS in the ER-positive
(n¼39) and ER-negative (n¼12) population was 8.9 (95% CI,
6.7–11.0) and 4.0 (95% CI, 1.4–8.2) months, respectively.
Median overall survival was 29.2 months (95% CI, 18.2–40.1 –
Figure 2).
The majority of patients received further lines of treatment after
discontinuation of study therapy: chemotherapy (85% of patients),
hormone therapy (54%) and radiotherapy (33%).
Drug delivery
The median number of cycles was seven (range: 1–58). Thirteen
patients received study treatment for more than 40 weeks, and
eight patients were treated for more than 1 year. The median
relative dose intensity of oral vinorelbine and capecitabine was
86.8 and 86.7%, respectively. Dose escalation of oral vinorelbine
was achieved in more than 90% of the patients. In 22 patients
(41%), the dose of one or both of the agents was reduced.
Every oral vinorelbine intake scheduled at day 1 could be
administered and only 6.2% of the doses planned at day 8 had
to be omitted.
In eight patients (14.8%), G-CSF was administered to manage
neutropaenia with a curative intent. Two of these patients also
received G-CSF with a preventive purpose. In all, G-CSF was
administered in 14 cycles (2.8%).
Treatment-related toxicity
Table 4 shows the incidence of the most common grade 3–4 side
effects related to treatment. The most frequent haematological
toxicity was neutropaenia, with grade 3–4 neutropaenia being
observed in 49% of patients. Neutropaenia was usually brief and
infrequently associated with infections. Only two patients (3.8%)
experienced febrile neutropaenia. Three additional patients (5.6%)
had documented infection associated with grade 3–4 neutropaenia
(one fatal septicaemia, one pneumonia and one urinary tract
infection). The septic death occurred in a 65-year-old patient with
a medical history of non-insulin-dependent diabetes mellitus and a
mitral valve replacement who presented, during the second cycle, a
positive blood culture in a context of grade 4 neutropaenia and
grade 3 diarrhoea.
Non-haematological toxicities were mild. The main grade 3
gastrointestinal adverse event was vomiting, which was seen in
9.3% of patients and in 1% of cycles. The incidence of grade 3–4
diarrhoea was observed in 3.7% of patients and in 0.6% of cycles
without any grade 4. Grade 2 alopaecia was observed in 9.3% and
no grade 3–4 neuropathy was observed.
DISCUSSION
This multicentre study confirms the efficacy of oral vinorelbine
with capecitabine previously seen in other studies, with a consis-
tent response rate of more than 50% (Delcambre et al, 2005; Finek
et al, 2009; Nole et al, 2009). The response rate in our trial is
comparable with the activity observed with intravenous combina-
tions. Moreover, a similar response rate was achieved in the critical
segment of patients having visceral metastases. Disease control was
obtained in two-thirds of the patients.
Secondary efficacy end points were also very encouraging: median
PFS was 8.4 months and median overall survival was 29.2 months.
There is little evidence from trials reported that major
differences exist between many commonly used chemotherapy
regimens (Wilcken and Dear, 2008). Among them, the combina-
tions of a taxane with an antimetabolite have been evaluated in two
major phase III trials (O’Shaughnessy et al, 2002; Albain et al,
2008). The activity observed with the combination of oral
vinorelbine and capecitabine in our trial compares favourably
with any of these regimens and provides a strong argument for its
development in randomised, comparative trials with any of them.
Table 3 Subanalysis of responses according to patients’ characteristics
Overall response rate (RECIST) (%)
All evaluable patients (n¼49) 51.0
Liver metastases (n¼23) 52.2
No prior chemotherapy (n¼16) 68.8
Prior anthracycline-based chemotherapy without taxane (n¼23) 39.1
Prior anthracycline+taxane (n¼5) 40.0
Prior CMF (n¼5) 60.0
Prior hormone therapy (n¼36) 55.6
Prior hormone therapy for MBC (n¼25) 56.0
Triple-negative disease (n¼9) 22.2
CMF¼cyclophosphamide, methotrexate, 5-FU; MBC¼metastatic breast cancer.
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Figure 1 Progression-free survival (months) intent-to-treat analysis.
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Figure 2 Overall survival (months) intent-to-treat analysis.
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line treatment for HER2-negative MBC patients, the combination
of paclitaxel and bevacizumab vs paclitaxel alone have been
published recently (Miller et al, 2007). The patient populations
entered in this study and in our trial present some similar
characteristics (around one-third of patients without any previous
chemotherapy and about 10% of previous anthracycline and
taxane in early-stage setting). There is no major difference in the
outcome of patients in terms of overall response rate and median
overall survival between our trial and the paclitaxel–bevacizumab
regimen. Moreover, the selection of patients who may benefit from
a bevacizumab-based regimen is not clear yet, this fact being a
critical issue because of its high cost.
The toxicities associated with oral vinorelbine and capecitabine
were predictable and manageable. As in other phase II studies
evaluating this regimen, significant haematological and non-
haematological adverse events were not frequently observed.
Nevertheless, as oral chemotherapy is largely taken at home by
patients, it is recommended to provide them with adequate
information about the measures to be taken in case of gastro-
intestinal adverse events and to manage them appropriately. The
rate of alopaecia in patients receiving this combination was
particularly low.
The good tolerability of the combination is apparent from
the long duration of therapy in our study. Chemotherapy
could be continued until disease progression, with few patients
requiring a cessation of treatment because of intolerable
adverse effects. The median number of cycles given was seven,
and some patients received treatment for more than 1 year.
Two meta-analyses comparing longer vs shorter chemotherapy
duration in MBC patients have shown that a longer duration was
linked with a survival benefit (Coates et al, 2003; Gennari et al,
2008).
Several surveys have shown that, provided efficacy and
tolerability are not compromised, most patients prefer oral to
intravenous chemotherapy (Liu et al, 1997; Findlay et al, 2008).
Oral chemotherapy may reduce anxiety in patients who are
afraid of injections. Whether it is administered at home or at
the hospital, it reduces treatment-related constraints by requiring
fewer and shorter hospital visits and has a smaller impact
on daily activities (Findlay et al, 2008). Therefore, with a similar
efficacy and fewer constraints, this all-oral combination
could be considered as being more efficient than intravenous
treatments.
In conclusion, the oral vinorelbine/capecitabine combination
evaluated in this study is effective and well tolerated. This, together
with all the benefits of an oral treatment, the possi-
bility of a longer duration of chemotherapy and of a prolonged
infusion-free survival, makes it an attractive regimen that could be
proposed as a valid option in first line for HER2-negative, MBC
patients.
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Table 4 Treatment-related adverse events
Per patient (%) N¼53
a Per cycle (%) N¼496
Adverse events by NCI/CTC v.2.0 Grade 3 Grade 4 Grade 3 Grade 4
Anaemia 1.9 1.9 0.2 0.2
Leukopaenia 17.0 11.3 3.6 1.4
Neutropaenia 26.4 22.6 6.5 3.0
Thrombocytopaenia 1.9 0 0.2 0
Febrile neutropaenia 3.8 0.4
Per patient (%) N¼54 Per cycle (%) N¼499
Grade 3 Grade 4 Grade 3 Grade 4
Nausea 3.7 0 0.4 0
Vomiting 9.3 0 1.0 0
Diarrhoea 3.7 0 0.6 0
Stomatitis 5.6 1.9 0.6 0.2
Hand–foot syndrome 3.7 0 0.8 0
Fatigue 7.4 0 1.2 0
Infection with G3/4 neutropaenia 3.7 1.9 0.6 0.2
Infection without G3/4 neutropaenia 3.7 0 0.4 0
Thrombosis/embolism 1.9 1.9 0.2 0.2
Anorexia 1.9 0 0.4 0
Grade 1 Grade 2
Alopaecia 16.7 9.3
aOne patient was not evaluable for haematological adverse events.
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